<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620124</url>
  </required_header>
  <id_info>
    <org_study_id>T5/2013</org_study_id>
    <nct_id>NCT02620124</nct_id>
  </id_info>
  <brief_title>GnRH Agonist as Luteal Support in FET Cycles</brief_title>
  <official_title>GnRH Anonist as Luteal Support in Frozen-thawed Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Back ground: A single dose of GnRH analogue in the luteal phase is reported to improve the
      outcome of IVF/ICSI treatments but the effect in FET cycles has not been reported.

      Aim: To compare the results of frozen thawed embryo transfers with and without GnRHa analogue
      support Primary end point: IR, PR, on going PR Secondary end point: hCH, E2 and progesterone
      levels 14 days after thawing
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>five weeks after the embryo transfer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>five weeks after the embryo transfer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>ten weeks after the embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hCG- level</measure>
    <time_frame>14 days after thawing of the embryos</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Natural cycle, control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment cycles with normal luteal support with progesteron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural cycle, intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormone replacement cycle, control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard hormone replacement cycle with estrogen and progesteron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormone replacement cycle, intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natural cycle: Triptorelin acetate 0.1 mg</intervention_name>
    <description>A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally</description>
    <arm_group_label>Natural cycle, intervention</arm_group_label>
    <arm_group_label>Hormone replacement cycle, intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone replacement cycle and triptorelin acetate 0.1 mg</intervention_name>
    <description>A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support</description>
    <arm_group_label>Hormone replacement cycle, intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 - 45 year old women comig to frozen thawed embryo transfer

        Exclusion Criteria:

          -  The age of the woman over 42 years during the initial ICF/ICSI- treatment from which
             the embryos derive

          -  Abnormal uterus

          -  Known abnormality of karyotype of the woman or her partner

          -  Severe male factor as an exclusive reason for subfertility

          -  Allegy for triptorelin acetate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Varpu Jokimaa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital District of the South-West Finland</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

